EPTINEZUMAB JJMR

N/A

Manufactured by Lundbeck Pharmaceuticals LLC

13,519 FDA adverse event reports analyzed

Last updated: 2026-04-14

About EPTINEZUMAB JJMR

EPTINEZUMAB JJMR is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Lundbeck Pharmaceuticals LLC. The most commonly reported adverse reactions for EPTINEZUMAB JJMR include DRUG INEFFECTIVE, MIGRAINE, HEADACHE, THERAPEUTIC RESPONSE SHORTENED, NAUSEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for EPTINEZUMAB JJMR.

Top Adverse Reactions

DRUG INEFFECTIVE1,954 reports
MIGRAINE1,366 reports
HEADACHE903 reports
THERAPEUTIC RESPONSE SHORTENED511 reports
NAUSEA500 reports
FATIGUE453 reports
DRUG EFFECT LESS THAN EXPECTED337 reports
THROAT IRRITATION322 reports
DIZZINESS308 reports
PRURITUS284 reports
NASAL CONGESTION228 reports
VOMITING182 reports
DYSPNOEA180 reports
HYPERSENSITIVITY180 reports
MALAISE162 reports
COVID 19151 reports
CHEST DISCOMFORT148 reports
RASH144 reports
COUGH143 reports
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION137 reports
RHINORRHOEA128 reports
THERAPEUTIC RESPONSE DECREASED126 reports
OFF LABEL USE124 reports
OROPHARYNGEAL PAIN123 reports
ADVERSE DRUG REACTION121 reports
FEELING ABNORMAL118 reports
PAIN113 reports
THERAPEUTIC RESPONSE DELAYED112 reports
NASOPHARYNGITIS108 reports
CONSTIPATION104 reports
FLUSHING98 reports
PRODUCT DOSE OMISSION ISSUE98 reports
INSOMNIA96 reports
ARTHRALGIA92 reports
URTICARIA91 reports
PARAESTHESIA86 reports
PNEUMONIA85 reports
BLOOD PRESSURE INCREASED83 reports
SNEEZING79 reports
CHEST PAIN77 reports
FALL77 reports
ALOPECIA76 reports
ANXIETY76 reports
HYPERTENSION75 reports
SOMNOLENCE70 reports
CONDITION AGGRAVATED68 reports
INFLUENZA LIKE ILLNESS68 reports
INFUSION RELATED REACTION68 reports
BRAIN FOG67 reports
DIARRHOEA66 reports
HYPOAESTHESIA64 reports
NECK PAIN63 reports
THERAPEUTIC PRODUCT EFFECT DECREASED63 reports
ABDOMINAL PAIN UPPER60 reports
ASTHENIA60 reports
ABDOMINAL PAIN57 reports
PYREXIA54 reports
DEPRESSION52 reports
PALPITATIONS50 reports
THROAT TIGHTNESS48 reports
ANAPHYLACTIC REACTION47 reports
PAIN IN EXTREMITY47 reports
SINUSITIS47 reports
CONFUSIONAL STATE46 reports
LOSS OF CONSCIOUSNESS46 reports
INFUSION SITE PAIN45 reports
MEMORY IMPAIRMENT45 reports
ABDOMINAL DISCOMFORT44 reports
WEIGHT INCREASED44 reports
WHEEZING44 reports
DYSPEPSIA43 reports
HEART RATE INCREASED43 reports
ILLNESS43 reports
VERTIGO43 reports
ERYTHEMA42 reports
GASTROINTESTINAL DISORDER42 reports
HYPOTENSION40 reports
INCORRECT DOSE ADMINISTERED40 reports
SURGERY40 reports
DECREASED APPETITE39 reports
DISTURBANCE IN ATTENTION39 reports
MUSCLE SPASMS39 reports
MUSCULOSKELETAL STIFFNESS39 reports
THERAPEUTIC PRODUCT EFFECT INCOMPLETE39 reports
FEELING HOT38 reports
INFUSION SITE EXTRAVASATION38 reports
MYALGIA38 reports
URINARY TRACT INFECTION38 reports
WEIGHT DECREASED38 reports
HYPERHIDROSIS37 reports
DEATH35 reports
ABDOMINAL DISTENSION34 reports
MATERNAL EXPOSURE DURING PREGNANCY34 reports
DYSPHONIA33 reports
SUICIDAL IDEATION33 reports
CHILLS32 reports
DRUG HYPERSENSITIVITY32 reports
GAIT DISTURBANCE32 reports
HEAD DISCOMFORT32 reports
INFLUENZA32 reports

Report Outcomes

Out of 8,120 classified reports for EPTINEZUMAB JJMR:

Serious 21.8%Non-Serious 78.2%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female4,817 (86.0%)
Male786 (14.0%)
Unknown1 (0.0%)

Reports by Age

Age 54158 reports
Age 49151 reports
Age 47150 reports
Age 48149 reports
Age 53142 reports
Age 55139 reports
Age 50138 reports
Age 44137 reports
Age 51137 reports
Age 61137 reports
Age 57136 reports
Age 60135 reports
Age 46130 reports
Age 45128 reports
Age 58123 reports
Age 40120 reports
Age 52119 reports
Age 42116 reports
Age 62116 reports
Age 56114 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with EPTINEZUMAB JJMR?

This profile reflects 13,519 FDA FAERS reports that mention EPTINEZUMAB JJMR. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for EPTINEZUMAB JJMR?

Frequently reported terms in FAERS include DRUG INEFFECTIVE, MIGRAINE, HEADACHE, THERAPEUTIC RESPONSE SHORTENED, NAUSEA, FATIGUE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures EPTINEZUMAB JJMR?

Labeling and FAERS entries often list Lundbeck Pharmaceuticals LLC in connection with EPTINEZUMAB JJMR. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.